Skip to main content

Coherent CEO Jim Anderson and Other Executives Will Share Industry Insights at OFC 2025

PITTSBURGH, March 06, 2025 (GLOBE NEWSWIRE) — Coherent Corp. (NYSE: COHR), a global leader in photonics, announces its executives’ participation in key thought leadership panels at OFC 2025, the premier global event for optical networking and communications. Coherent Chief Executive Officer Jim Anderson will be a featured panelist on the CEO Panel at the Optica Executive Forum, taking place on Monday, March 31, at the Marriott Marquis San Francisco. He will share his perspectives on the pivotal role that Coherent plays in optical networking and the AI revolution. Additionally, Chief Technology Officer Dr. Julie Eng will address the “Status of Photonic-enabled Modules” at the same event. Dr. Sanjai Parthasarathi, Chief Marketing Officer, will share his insights at one of OFC’s most highly attended events: the opening Market...

Continue reading

Arkansas Cooperative to Modernize Electric Grid with Itron’s Gen5 Riva Solution

Cooperative to Leverage Fiber Network to Improve Grid Resiliency and Reliability Across Rural Service Territory LIBERTY LAKE, Wash., March 06, 2025 (GLOBE NEWSWIRE) — Itron, Inc. (NASDAQ: ITRI), which is innovating new ways for utilities and cities to manage energy and water, and its channel partner, National Rural Telecommunications Cooperative (NRTC), are working together with Arkansas Valley Electric Cooperative Corporation (AVECC), to improve grid resiliency and reliability for AVECC’s members across the Arkansas River Valley. AVECC is leveraging its existing fiber optic network to unlock a broad range of applications at the grid edge. As part of the collaboration, AVECC is deploying Itron’s Gen5 Riva® smart meters and connecting them to Itron’s fiber-enabled communications technology. This smart grid project, which was awarded...

Continue reading

Cycurion (Nasdaq: CYCU) Partners with CentralSquare Technologies to Provide Public Safety IT Services Across the Country

FALLS CHURCH, Va., March 06, 2025 (GLOBE NEWSWIRE) — Cycurion, Inc. (Nasdaq: CYCU), a trusted leader in IT cybersecurity solutions and AI, announces a nationwide expansion of its strategic partnership with CentralSquare Technologies, LLC to deliver its IT services across the country. Through this collaboration, Cycurion will offer its highly effective project management, change management, curriculum development, and training services in partnership with CentralSquare Technologies outside of the Chicago area and expand to other large urban areas in the United States. Public Safety agencies are constantly seeking ways to improve response times and increase the amount of information available to first responders. With CentralSquare Technologies’ public safety products and Cycurion’s IT services, the companies believe that public...

Continue reading

Leading Government Contracts Partner Eric Crusius Joins Hunton in Washington

Eric Crusius, Partner, HuntonEric Crusius, Partner, HuntonWashington, March 06, 2025 (GLOBE NEWSWIRE) — Hunton Andrews Kurth LLP is pleased to welcome new partner Eric S. Crusius, a veteran government contracts attorney who will lead the firm’s practice in Washington.* Crusius, who joins the firm from Holland & Knight LLP, has more than two decades of experience in private practice advising state and federal government contractors. His practice includes representing clients prosecuting and intervening in bid protests before the U.S. Court of Federal Claims, U.S. Government Accountability Office, boards of contract appeals and other federal agencies. He advises clients on the Service Contract Act and related labor issues, domestic preferences, export controls, cybersecurity, subcontracting and teaming agreements, and...

Continue reading

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

VOQUEZNA® (vonoprazan) generated $55.3 million in 2024 net revenues in its first full year of launch, driven by strong demand, including $29.7 million in Q4, an 81% increase from Q3 Over 300,000 filled prescriptions for VOQUEZNA products, launch-to-date, approximately a 110% increase since last earnings report Phase 2 EoE trial for VOQUEZNA nearing initiation, with first patient enrollment planned for Q2 2025 Management to host conference call today, March 6, 2025, at 8:30 a.m. ETFLORHAM PARK, N.J., March 06, 2025 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business updates. “VOQUEZNA’s...

Continue reading

Global Uranium Corp. Signs Letter of Engagement with Big Rock Exploration to Advance Phase II Exploration at the Wyoming Group of Projects

Global Uranium Advances Exploration Strategy with Phase II Program in Wyoming CALGARY, Alberta, March 06, 2025 (GLOBE NEWSWIRE) — Global Uranium Corp. (CSE: GURN | OTC: GURFF | FRA: Q3J) (the “Company”) is pleased to announce that it has signed a Letter of Engagement (“LOE”) with Big Rock Exploration LLC (“BRE”) to commence Phase II exploration activities on the Company’s Wyoming Group of Projects. The engagement with BRE represents the next step forward in refining exploration targets across the Airline, Jeep, WAC, Big Bend, and Jabs properties, located in key uranium districts within Wyoming. Under the terms of the engagement, BRE will develop an exploration framework by integrating historical data, geologic mapping, and radiometric survey results to identify high-priority drill targets. This initiative builds...

Continue reading

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

Trial to explore novel combination therapy for patients with recurrent Small Cell Lung Cancer who have failed frontline treatment Fully funded by the U.S. Veterans’ Administration Special Emphasis Panel on Precision Oncology Trial builds on promising clinical evidence supporting a PARP inhibitor and temozolomide combination in Small Cell Lung CancerBoston (March 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—today announced plans for a Phase 2 trial evaluating the combination of stenoparib with temozolomide, a DNA-alkylating chemotherapy agent, for the treatment of recurrent Small Cell Lung Cancer (SCLC). The trial is fully funded by the U.S. Veterans Administration...

Continue reading

Macerich Advances HiFi, Outdoor Mixed-Use Development at FlatIron Crossing in Colorado, Names Entertainment Anchor

Strategic Investment in Its Best Properties is Key Aspect of Macerich’s Path Forward PlanA Media Snippet accompanying this announcement is available by clicking on this link. SANTA MONICA, Calif., March 06, 2025 (GLOBE NEWSWIRE) — Macerich (NYSE: MAC), one of the nation’s leading owners, operators and developers of major retail properties in top markets, today announced that Pindustry will anchor HiFi, its mixed-use outdoor development project adjacent to premier retail destination FlatIron Crossing. HiFi at FlatIron Crossing, Macerich’s thriving property in Colorado’s busy Denver-Boulder corridor, blends multifamily living, unique shopping, dining and entertainment with lush green spaces to create a new destination for all things fun. Pindustry – a two-level, locally owned entertainment destination – will join NOVEL FlatIron...

Continue reading

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

HOUSTON, March 06, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Rhenium (186Re) Obisbemeda for the treatment of leptomeningeal metastases (LM) in patients with lung cancer. “Receiving Orphan Drug Designation for Rhenium (186Re) Obisbemeda marks a significant milestone in our efforts to develop a much-needed therapy for lung cancer patients with leptomeningeal metastases,” said Mike Rosol, Ph.D., Plus Therapeutics Chief Development Officer. “These patients currently have limited treatment options, and the growing incidence...

Continue reading

Viasat and partners deliver first-of-its-kind direct-to-device demonstration in South America

Viasat and its ecosystem partners GuardianSat, Quectel, and Acceleronix, successfully complete trial in Brazil to showcase direct-to-device connectivity for the automotive industryViasat and partners deliver first-of-its-kind direct-to-device demonstration in South AmericaViasat and its ecosystem partners GuardianSat, Quectel, and Acceleronix, successfully complete trial in Brazil to showcase direct-to-device connectivity for the automotive industryCARLSBAD, Calif., March 06, 2025 (GLOBE NEWSWIRE) — Viasat, Inc. (NASDAQ: VSAT), a global leader in satellite communications, today announced the first-of-its-kind demonstration of direct-to-device (D2D) connectivity for the automotive sector — opening the door for widescale adoption of satellite connectivity for automotive use cases. In a country-first, the tests saw different...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.